

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 00,1214)

PATENT

In re Application of: Welcher et al. )

Serial No.: Unassigned )

Filed: November 28, 2000 )

For: Interleukin-1 )  
Receptor Antagonist-Like )  
Molecules and Uses Thereof )

Before the Examiner: Unassigned

Group Art Unit: Unassigned

Assistant Commissioner for Patents  
Washington, D.C. 20231




Sir/Madam:

**STATEMENT UNDER 37 C.F.R. § 1.821**

The undersigned representative hereby declares that the content of the paper and computer readable copies of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are identical in content. The 3.5" diskette contains an IBM compatible dos-text file of the sequence listing named "001214seq.txt."

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Dated: November 28, 2000

By:   
Kevin E. Noonan, Ph.D.  
Reg. No. 35,303

# SEQUENCE LISTING

<110> Welcher, Andrew A.  
Jing, Shugian  
Luethy, Roland

<120> Interleukin-1 Receptor Antagonist-Like Molecules and  
Uses Thereof

<130> 00-1214

<140>

<141>

<150> 60/170,052

<151> 1999-12-10

<160> 18

<170> PatentIn Ver. 2.0

<210> 1

<211> 1244

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (301)..(774)

<400> 1

```
gtgttgctcc actgtcagtc ctccagagcc tcaagagatc tttgggccat atcagctttc 60
tttccaaaat gaacacaccc aggggcagga aagaatgctc tttccttggt cattaagggg 120
cctggggagtc ctggaccagc ttttcatgca gctagaccac ttacatgcaa ctagagcctt 180
gactttgaaa cgaggggacaa aagcatctct tgctaaagggt aacttctgct gcttagaacc 240
cagcctcctc accaccatct gatctatctt gttctcttca caaaaggctc tgaagacatc 300

atg aac cca caa cgg gag gca gca ccc aaa tcc tat gct att cgt gat 348
Met Asn Pro Gln Arg Glu Ala Ala Pro Lys Ser Tyr Ala Ile Arg Asp
  1           5           10          15

tct cga cag atg gtg tgg gtc ctg agt gga aat tct tta ata gca gct 396
Ser Arg Gln Met Val Trp Val Leu Ser Gly Asn Ser Leu Ile Ala Ala
      20           25           30

cct ctt agc cgc agc att aag cct gtc act ctt cat tta ata gcc tgt 444
Pro Leu Ser Arg Ser Ile Lys Pro Val Thr Leu His Leu Ile Ala Cys
      35           40           45

aga gac aca gaa ttc agt gac aag gaa aag ggt aat atg gtt tac ctg 492
Arg Asp Thr Glu Phe Ser Asp Lys Glu Lys Gly Asn Met Val Tyr Leu
      50           55           60
```

gga atc aag gga aaa gat ctc tgt ctc ttc tgt gca gaa att cag ggc 540  
 Gly Ile Lys Gly Lys Asp Leu Cys Leu Phe Cys Ala Glu Ile Gln Gly  
 65 70 75 80

aag cct act ttg cag ctt aag gaa aaa aat atc atg gac ctg tat gtg 588  
 Lys Pro Thr Leu Gln Leu Lys Glu Lys Asn Ile Met Asp Leu Tyr Val  
 85 90 95

gag aag aaa gca cag aag ccc ttt ctc ttt ttc cac aat aaa gaa ggc 636  
 Glu Lys Lys Ala Gln Lys Pro Phe Leu Phe Phe His Asn Lys Glu Gly  
 100 105 110

tcc act tct gtc ttt cag tca gtc tct tac cct ggc tgg ttc ata gcc 684  
 Ser Thr Ser Val Phe Gln Ser Val Ser Tyr Pro Gly Trp Phe Ile Ala  
 115 120 125

acc tcc acc aca tca gga cag ccc atc ttt ctc acc aag gag aga ggc 732  
 Thr Ser Thr Thr Ser Gly Gln Pro Ile Phe Leu Thr Lys Glu Arg Gly  
 130 135 140

ata act aat aac act aac ttc tac tta gat tct gtg gaa taa 774  
 Ile Thr Asn Asn Thr Asn Phe Tyr Leu Asp Ser Val Glu  
 145 150 155

atccagccta ggctgtgggt ggctgggtcc aggatagaga atcaagctgt cagagtcac 834

ttaacagatc attatgcgac tgagttcact agcagttcag cccatccata gcttacctca 894

ttcttactat ccaaaagcca cctcctcctc caaacatcca tttctgtacc aagaccctca 954

ctcgaatgtc actatcccaa gatgaaacct aaaaatcact ttccattctt tcttgatctt 1014

acccccaccat ccactcagct gccatgcca gtttagtta cccccaaat gctgcttcat 1074

gcaaccttcc attcctattc cttttgcca cccatgatgt agagatgtgg attcatgaca 1134

ttttgttcat acaacttctt caataaaaca ttataatatg tgccccaaag ataaagctga 1194

agaatgagat gaatgtgaaa ttaaagggtt gcatgtcttc ctaatcctaa 1244

<210> 2

<211> 157

<212> PRT

<213> Homo sapiens

<400> 2

Met Asn Pro Gln Arg Glu Ala Ala Pro Lys Ser Tyr Ala Ile Arg Asp  
 1 5 10 15

Ser Arg Gln Met Val Trp Val Leu Ser Gly Asn Ser Leu Ile Ala Ala  
 20 25 30

Pro Leu Ser Arg Ser Ile Lys Pro Val Thr Leu His Leu Ile Ala Cys  
 35 40 45

Arg Asp Thr Glu Phe Ser Asp Lys Glu Lys Gly Asn Met Val Tyr Leu

60

Ile Thr Asn Asn Thr Asn Phe Tyr Leu Asp Ser Val Glu  
145 150 155

<213> Homo sapiens

Arg Lys Lys Asp Lys Asp Phe Ser Ser Met Arg Thr Asn Ile Gly Met  
145 150 155 160

Pro Gly Arg Met

<210> 4

<211> 158

<212> PRT

<213> Homo sapiens

<400> 4

Met Glu Lys Ala Leu Lys Ile Asp Thr Pro Gln Gln Gly Ser Ile Gln  
1 5 10 15

Asp Ile Asn His Arg Val Trp Val Leu Gln Asp Gln Thr Leu Ile Ala  
20 25 30

Val Pro Arg Lys Asp Arg Met Ser Pro Val Thr Ile Ala Leu Ile Ser  
35 40 45

Cys Arg His Val Glu Thr Leu Glu Lys Asp Arg Gly Asn Pro Ile Tyr  
50 55 60

Leu Gly Leu Asn Gly Leu Asn Leu Cys Leu Met Cys Ala Lys Val Gly  
65 70 75 80

Asp Gln Pro Thr Leu Gln Leu Lys Glu Lys Asp Ile Met Asp Leu Tyr  
85 90 95

Asn Gln Pro Glu Pro Val Lys Ser Phe Leu Phe Tyr His Ser Gln Ser  
100 105 110

Gly Arg Asn Ser Thr Phe Glu Ser Val Ala Phe Pro Gly Trp Phe Ile  
115 120 125

Ala Val Ser Ser Glu Gly Gly Cys Pro Leu Ile Leu Thr Gln Glu Leu  
130 135 140

Gly Lys Ala Asn Thr Thr Asp Phe Gly Leu Thr Met Leu Phe  
145 150 155

<210> 5

<211> 177

<212> PRT

<213> Homo sapiens

<400> 5

Met Glu Ile Cys Arg Gly Leu Arg Ser His Leu Ile Thr Leu Leu Leu  
1 5 10 15

Phe Leu Phe His Ser Glu Thr Ile Cys Arg Pro Ser Gly Arg Lys Ser  
20 25 30

Ser Lys Met Gln Ala Phe Arg Ile Trp Asp Val Asn Gln Lys Thr Phe  
35 40 45

Tyr Leu Arg Asn Asn Gln Leu Val Ala Gly Tyr Leu Gln Gly Pro Asn

50

55

60

Val Asn Leu Glu Glu Lys Ile Asp Val Val Pro Ile Glu Pro His Ala  
65 70 75 80

Leu Phe Leu Gly Ile His Gly Gly Lys Met Cys Leu Ser Cys Val Lys  
85 90 95

Ser Gly Asp Glu Thr Arg Leu Gln Leu Glu Ala Val Asn Ile Thr Asp  
100 105 110

Leu Ser Glu Asn Arg Lys Gln Asp Lys Arg Phe Ala Phe Ile Arg Ser  
115 120 125

Asp Ser Gly Pro Thr Thr Ser Phe Glu Ser Ala Ala Cys Pro Gly Trp  
130 135 140

Phe Leu Cys Thr Ala Met Glu Ala Asp Gln Pro Val Ser Leu Thr Asn  
145 150 155 160

Met Pro Asp Glu Gly Val Met Val Thr Lys Phe Tyr Phe Gln Glu Asp  
165 170 175

Glu

<210> 6

<211> 153

<212> PRT

<213> Homo sapiens

<400> 6

Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp Ser Gln Gln Lys  
1 5 10 15

Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala Leu His Leu Gln  
20 25 30

Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met Ser Phe Val Gln  
35 40 45

Gly Glu Glu Ser Asn Asp Lys Ile Pro Val Ala Leu Gly Leu Lys Glu  
50 55 60

Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys Asp Asp Lys Pro Thr Leu  
65 70 75 80

Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys Lys Lys Met Glu  
85 90 95

Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn Lys Leu Glu Phe  
100 105 110

Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr Ser Gln Ala Glu  
115 120 125

Asn Met Pro Val Phe Leu Gly Gly Thr Lys Gly Gly Gln Asp Ile Thr  
 130 135 140

Asp Phe Thr Met Gln Phe Val Ser Ser  
 145 150

<210> 7  
 <211> 11  
 <212> PRT  
 <213> Human immunodeficiency virus type 1

<400> 7  
 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10

<210> 8  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: internalizing  
 domain derived from HIV tat protein

<400> 8  
 Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10 15

<210> 9  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide 2362-94

<400> 9  
 catggacctg tatgtggaga aga 23

<210> 10  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide 2362-95

<400> 10  
 gccagggtaa gagactgact gaa 23

<210> 11  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide 870-02

<400> 11  
agcggataac aatttcacac agg 23

<210> 12  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide 2366-21

<400> 12  
gcctaggctg gatttattcc acag 24

<210> 13  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide 1019-06

<400> 13  
gctctaatac gactcactat aggg 24

<210> 14  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide 2362-98

<400> 14  
ctgatgtggt ggaggtggct at 22

<210> 15  
<211> 23  
<212> DNA  
<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence:  
Oligonucleotide 1340-35

<400> 15

cccagtcacg acgttgtaaa acg

23

<210> 16

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide 1019-05

<400> 16

tgaatttagg tgacactata gaagag

26

<210> 17

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide 2379-15

<400> 17

gtcctccaga gcctcaagag atc

23

<210> 18

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide 2375-10

<400> 18

ttaggattag gaagacatgc aaacc

25